ID-alG

CALORIE REDUCTION & WELL BEING

  • Fat & carb blocker
  • Body shape improvement
  • Weight-loss clinical studies

ID-alG TM is a brown seaweed extract derived from Ascophyllum nodosum and intended to help limit fat and sugar storage in the body and control weight.

Description

Ascophyllum nodosum is a species of brown algae belonging to the Fucaceae family. It is often found along the rocky coasts of the North Atlantic, where it forms dense colonies. Measuring up to 1 meter 50, it is harvested manually all year round. After being carefully selected in the ocean, the long brown algae fronds are checked again in the local factory before the first processing stages.

Rich in marine polyphenols content that blocks the activity of the two main digestive enzymes, lipase and amylase, ID-alGTM is a weight-loss solution for women and more specifically for 45 years & over.

Thanks to its potent inhibition activity on lipases and on alpha-amylases, ID-alGTM reduces fats and carbs assimilation, inducing a reduction of the caloric intake for a global weight control effect. This inhibition activity of theses enzymes is guaranteed to overpass 50% (in tubo test).

The latest clinical study1 conducted with ID-alGTM confirms its outstanding weight management properties:

  • Significant weight loss correlated with fat mass
  • Decrease in fat assimilation lowering body fat mass and abdominal & visceral fat
  • Significant reduction in carbs assimilation, leading to a decrease in glycated hemoglobin (HbA1C)
  • Body shape improvement
  • No signs of discomfort

Nexira delivers a high-performance ingredient in weight management, approved by the general satisfaction of consumers2

  • 76% were convince of the weight management effect of ID-alG™  
  • 72% would continue using ID-alG™

ID-alG TM is a natural ingredient manufactured in France, used in food supplements.

algue ID-alG ingredient

I am interested in ID-alG TM, please contact me.

Contact

Sources :
(1) Clinical study (2006): 16-weeks bi-centric double-blind randomized placebo-controlled study to evaluate ID-alG benefits and acceptability (400mg per day) on weight management
(2) Evaluation of IG-alGTM’s weight management effect on overweight women. Monocentric, randomized, placebo controlled clinical study run in March 2010, on 56 women using 400 mg of ID-alGTM daily for 8 weeks.

This communication is not intended to the final consumer. It provides scientific information for professionals only. Communications to the final consumer have to be checked according to local regulations in force, since the conditions of use are beyond our control. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.